Novotech Media Room
FEATURED ARTICLE
The Road Less Travelled – Navigation through the do’s and
don’ts of running Oncology studies in Asia Pacific
Clinical trials in the Asia Pacific are increasing exponentially. Numerous sponsors and
CROs have accessed this region in recent years to take advantage of high performing,
cost effective sites. Watch the online presentation >> |
|
|
Company News
Novotech CRO attracts investment for Asia Clinical Trial expansion
May 6, 2013
Sydney, Australia, 6 May, 2013 – Novotech, Australia’s largest independent
CRO today announced a funding injection from private equity firm Mercury
Capital - www.mercurycapital.com.au
“Novotech is focused on the fast-growing Asia region. We are already active in 10 countries in the region on behalf of our biotechnology and pharmaceutical clients. This investment will further accelerate our expansion plans.” read more >>
Herpes Zoster Novel Treatment Hope From Tasmanian Abalone Gets $1.2 Million Boost
June 15, 2011
Sydney, Australia, 23 May 2011 – Leading Australian contract clinical research company Novotech, Marine Biotechnology Australia Pty Ltd [MBA] and the University of Sydney today announced a new Herpes research collaboration backed by the Academic Research Council [ARC]. The team aims to commercialize a novel treatment for Herpes simplex and Herpes zoster utilizing an extract. read more >>
Novotech initiates cancer trials in Australia and New Zealand for Oncomed Pharmaceuticals
October 29, 2010
NOVOTECH INITIATES PHASE IB CANCER TRIALS IN AUSTRALIA AND NEW ZEALAND FOR CLIENT, ONCOMED PHARMACEUTICALS Sydney, Australia, 29 October 2010 – Novotech has announced initiation of three Phase Ib oncology trials at sites in Australia and New Zealand to test the safety, efficacy and pharmacokinetics of client OncoMed’s humanized monoclonal antibody product designed to target. read more >> |
|
Media Reports
Alchemia Recruits Full Patient Quota to Pivotal Phase III HAIrinotecan Trial in Metastatic Colorectal Cancer
February 4, 2013
Brisbane-based drug discovery and development company Alchemia Limited (ASX: ACL) has recruited the 390th patient to its pivotal Phase III clinical trial
of the Company’s lead cancer drug, HA-Irinotecan, as per its study protocol.
read more >>
TheraVida Initiates Phase 2 Trial of THVD-201 for Overactive Bladder and Urinary Incontinence: selects Novotech
July 5, 2011
Multi-national Study to be Conducted by Novotech in Australia, New Zealand, and South Korea MOUNTAIN VIEW, California, and SYDNEY, Australia, May 16, 2011 /PRNewswire-iReach/ — TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, announced the start of a Phase 2 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). Novotech, a leading Asia Pacific contract research organization, has been selected to manage the study for TheraVida.
read more >>
Novotech in new research collaboration: Biotechnology News
July 5, 2011
LEADING Australian contract clinical research company Novotech, Marine Biotechnology Australia and the University of Sydney are taking part in a new herpes research collaboration backed by the Academic Research Council (ARC). read more >> |
|
|
|
